Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
EyePoint sees cash able to fund planned operations through end of 2022 » 07:24
05/05/21
05/05
07:24
05/05/21
07:24
EYPT

EyePoint

$10.43 /

-0.25 (-2.34%)

The company said:…

The company said: "We expect the cash on hand at March 31, 2021 and expected net cash inflows from our product sales will enable us to fund our current and planned operations through the end of 2022."

ShowHide Related Items >><<
EYPT EyePoint
$10.43 /

-0.25 (-2.34%)

EYPT EyePoint
$10.43 /

-0.25 (-2.34%)

03/01/21
Fly Intel: Top five analyst initiations
03/01/21 Cowen
EyePoint initiated with an Outperform at Cowen
01/27/21 Cantor Fitzgerald
Cantor Fitzgerald starts EyePoint at Overweight with $22 price target
01/27/21 Cantor Fitzgerald
EyePoint initiated with an Overweight at Cantor Fitzgerald
EYPT EyePoint
$10.43 /

-0.25 (-2.34%)

  • 02
    Feb
Earnings
EyePoint reports Q1 EPS (50c), consensus (46c) » 07:23
05/05/21
05/05
07:23
05/05/21
07:23
EYPT

EyePoint

$10.43 /

-0.25 (-2.34%)

Reports Q1 revenue $7.3M,…

Reports Q1 revenue $7.3M, consensus $7.93M.

ShowHide Related Items >><<
EYPT EyePoint
$10.43 /

-0.25 (-2.34%)

EYPT EyePoint
$10.43 /

-0.25 (-2.34%)

03/01/21
Fly Intel: Top five analyst initiations
03/01/21 Cowen
EyePoint initiated with an Outperform at Cowen
01/27/21 Cantor Fitzgerald
Cantor Fitzgerald starts EyePoint at Overweight with $22 price target
01/27/21 Cantor Fitzgerald
EyePoint initiated with an Overweight at Cantor Fitzgerald
EYPT EyePoint
$10.43 /

-0.25 (-2.34%)

  • 02
    Feb
Over a week ago
Conference/Events
EyePoint participates in a conference call with Cantor Fitzgerald » 12:25
04/16/21
04/16
12:25
04/16/21
12:25
EYPT

EyePoint

$9.43 /

-0.175 (-1.82%)

Conference call with…

Conference call with President & CEO Lurker, Chief Strategic Officer Duker and CFO Elston discuss EYP-1901 on a conference call to be held on April 16 at 1 pm hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
EYPT EyePoint
$9.43 /

-0.175 (-1.82%)

EYPT EyePoint
$9.43 /

-0.175 (-1.82%)

03/01/21
Fly Intel: Top five analyst initiations
03/01/21 Cowen
EyePoint initiated with an Outperform at Cowen
01/27/21 Cantor Fitzgerald
Cantor Fitzgerald starts EyePoint at Overweight with $22 price target
01/27/21 Cantor Fitzgerald
EyePoint initiated with an Overweight at Cantor Fitzgerald
EYPT EyePoint
$9.43 /

-0.175 (-1.82%)

  • 02
    Feb
Conference/Events
EyePoint participates in a conference call with Cantor Fitzgerald » 10:12
04/16/21
04/16
10:12
04/16/21
10:12
EYPT

EyePoint

$9.18 /

-0.425 (-4.42%)

Conference call with…

Conference call with President & CEO Lurker, Chief Strategic Officer Duker and CFO Elston discuss EYP-1901 on a conference call to be held on April 16 at 1 pm hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
EYPT EyePoint
$9.18 /

-0.425 (-4.42%)

EYPT EyePoint
$9.18 /

-0.425 (-4.42%)

03/01/21
Fly Intel: Top five analyst initiations
03/01/21 Cowen
EyePoint initiated with an Outperform at Cowen
01/27/21 Cantor Fitzgerald
Cantor Fitzgerald starts EyePoint at Overweight with $22 price target
01/27/21 Cantor Fitzgerald
EyePoint initiated with an Overweight at Cantor Fitzgerald
EYPT EyePoint
$9.18 /

-0.425 (-4.42%)

  • 02
    Feb
Over a month ago
Hot Stocks
EyePoint expects cash to fund planned operations through 2Q22 » 07:11
03/04/21
03/04
07:11
03/04/21
07:11
EYPT

EyePoint

$11.65 /

-0.51 (-4.19%)

The company said,"We…

The company said,"We expect the cash on hand at December 31, 2020 together with the approximate $108 million of net proceeds from the February 2021 public stock offering and expected net cash inflows from our product sales will enable us to fund our current and planned operations through the second quarter of 2022."

ShowHide Related Items >><<
EYPT EyePoint
$11.65 /

-0.51 (-4.19%)

EYPT EyePoint
$11.65 /

-0.51 (-4.19%)

03/01/21
Fly Intel: Top five analyst initiations
03/01/21 Cowen
EyePoint initiated with an Outperform at Cowen
01/27/21 Cantor Fitzgerald
Cantor Fitzgerald starts EyePoint at Overweight with $22 price target
01/27/21 Cantor Fitzgerald
EyePoint initiated with an Overweight at Cantor Fitzgerald
EYPT EyePoint
$11.65 /

-0.51 (-4.19%)

  • 02
    Feb
Earnings
EyePoint reports Q4 EPS ($1.07), consensus (17c) » 07:10
03/04/21
03/04
07:10
03/04/21
07:10
EYPT

EyePoint

$11.65 /

-0.51 (-4.19%)

Reports Q4 revenue $7.1M,…

Reports Q4 revenue $7.1M, consensus $20.44M. "This year was transformative for EyePoint, across all clinical, financial and commercial fronts, despite the impact of COVID-19 on our business. In December 2020, we filed the IND for EYP-1901, a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration, and the first patient was dosed in January. We are excited about the potential for EYP-1901 to dramatically transform the treatment of wet AMD offering patients the opportunity for fewer treatments and improved results," said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals. "On the commercial front, despite the challenges of COVID-19 with closures in the earlier part of the year, we were pleased to see a return of customer demand of our commercial products to near pre-COVID levels in the second half of 2020. In addition to the advancement of EYP-1901, we have made tremendous progress to improve our balance sheet, including a recent upsized follow-on stock offering with $115.1 million of gross proceeds and a $16.5 million royalty monetization with $15 million applied to reduce outstanding debt obligations."

ShowHide Related Items >><<
EYPT EyePoint
$11.65 /

-0.51 (-4.19%)

EYPT EyePoint
$11.65 /

-0.51 (-4.19%)

03/01/21
Fly Intel: Top five analyst initiations
03/01/21 Cowen
EyePoint initiated with an Outperform at Cowen
01/27/21 Cantor Fitzgerald
Cantor Fitzgerald starts EyePoint at Overweight with $22 price target
01/27/21 Cantor Fitzgerald
EyePoint initiated with an Overweight at Cantor Fitzgerald
EYPT EyePoint
$11.65 /

-0.51 (-4.19%)

  • 02
    Feb
Initiation
Fly Intel: Top five analyst initiations » 09:53
03/01/21
03/01
09:53
03/01/21
09:53
ATC

Atotech

$21.00 /

+0.65 (+3.19%)

, SNSE

Sensei Biotherapeutics

$17.87 /

+1.14 (+6.81%)

, SAM

Boston Beer

$1,055.00 /

+21.31 (+2.06%)

, ALKS

Alkermes

$19.30 /

+0.22 (+1.15%)

, EYPT

EyePoint

$10.90 /

+ (+0.00%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Atotech (ATC) initiated with a Buy at Deutsche Bank, Jefferies and BofA, initiated with an Overweight at JPMorgan, initiated with an Outperform at Credit Suisse, RBC Capital and BMO Capital. 2. Sensei Biotherapeutics (SNSE) initiated with an Overweight at Piper Sandler, a Buy at Citi and an Outperform at Oppenheimer. 3. Boston Beer (SAM) initiated with an Overweight at Morgan Stanley. 4. Alkermes (ALKS) assumed with a Hold at Jefferies. 5. EyePoint (EYPT) initiated with an Outperform at Cowen. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
SAM Boston Beer
$1,055.00 /

+21.31 (+2.06%)

EYPT EyePoint
$10.90 /

+ (+0.00%)

ALKS Alkermes
$19.30 /

+0.22 (+1.15%)

ATC Atotech
$21.00 /

+0.65 (+3.19%)

03/01/21 Deutsche Bank
Atotech initiated with a Buy at Deutsche Bank
03/01/21 Jefferies
Atotech initiated with a Buy at Jefferies
03/01/21 JPMorgan
Atotech initiated with an Overweight at JPMorgan
03/01/21 Credit Suisse
Atotech initiated with an Outperform at Credit Suisse
SNSE Sensei Biotherapeutics
$17.87 /

+1.14 (+6.81%)

03/01/21 Oppenheimer
Sensei Biotherapeutics initiated with an Outperform at Oppenheimer
03/01/21 Citi
Sensei Biotherapeutics initiated with a Buy at Citi
03/01/21 Piper Sandler
Sensei Biotherapeutics initiated with an Overweight at Piper Sandler
SAM Boston Beer
$1,055.00 /

+21.31 (+2.06%)

03/01/21 Morgan Stanley
Boston Beer initiated with an Overweight at Morgan Stanley
02/18/21 Evercore ISI
Boston Beer price target raised to $1,300 from $1,150 at Evercore ISI
02/18/21 Deutsche Bank
Boston Beer likely to selloff post earnings, says Deutsche Bank
02/18/21 UBS
Boston Beer price target raised to $1,350 from $1,080 at UBS
ALKS Alkermes
$19.30 /

+0.22 (+1.15%)

03/01/21 Jefferies
Alkermes assumed with a Hold at Jefferies
01/12/21 Evercore ISI
Alkermes IL-2 looking 'more and more intriguing,' says Evercore ISI
01/07/21 Mizuho
Alkermes price target raised to $28 from $24 at Mizuho
12/10/20 Goldman Sachs
Goldman 'welcomes' Alkermes' strategic initiatives, needs to see company execute
EYPT EyePoint
$10.90 /

+ (+0.00%)

03/01/21 Cowen
EyePoint initiated with an Outperform at Cowen
01/27/21 Cantor Fitzgerald
Cantor Fitzgerald starts EyePoint at Overweight with $22 price target
01/27/21 Cantor Fitzgerald
EyePoint initiated with an Overweight at Cantor Fitzgerald
01/12/21 B. Riley
EyePoint price target raised to $8.50 from $5 at B. Riley Securities
SAM Boston Beer
$1,055.00 /

+21.31 (+2.06%)

EYPT EyePoint
$10.90 /

+ (+0.00%)

ALKS Alkermes
$19.30 /

+0.22 (+1.15%)

  • 02
    Feb
  • 04
    Feb
  • 04
    Feb
SAM Boston Beer
$1,055.00 /

+21.31 (+2.06%)

ATC Atotech
$21.00 /

+0.65 (+3.19%)

ALKS Alkermes
$19.30 /

+0.22 (+1.15%)

Initiation
EyePoint initiated with an Outperform at Cowen » 07:33
03/01/21
03/01
07:33
03/01/21
07:33
EYPT

EyePoint

$10.90 /

-0.08 (-0.73%)

Cowen analyst Ken…

Cowen analyst Ken Cacciatore initiated coverage of EyePoint with an Outperform rating and $25 price target. The company is leveraging its commercially-validated sustained release Durasert technology for EYP-1901 for wet AMD, said Cacciatore, who believes that EYP-1901 could represent a greater than $500M opportunity if successful.

ShowHide Related Items >><<
EYPT EyePoint
$10.90 /

-0.08 (-0.73%)

EYPT EyePoint
$10.90 /

-0.08 (-0.73%)

01/27/21 Cantor Fitzgerald
Cantor Fitzgerald starts EyePoint at Overweight with $22 price target
01/27/21 Cantor Fitzgerald
EyePoint initiated with an Overweight at Cantor Fitzgerald
01/12/21 B. Riley
EyePoint price target raised to $8.50 from $5 at B. Riley Securities
01/07/21 Alliance Global Partners
Iluvien deal shows valuation disconnect at Alimera, says Alliance Global Partners
EYPT EyePoint
$10.90 /

-0.08 (-0.73%)

  • 02
    Feb
Syndicate
EyePoint files to sell 3.01M shares of common stock for holders  16:07
02/12/21
02/12
16:07
02/12/21
16:07
EYPT

EyePoint

$13.20 /

-0.44 (-3.23%)

 
ShowHide Related Items >><<
EYPT EyePoint
$13.20 /

-0.44 (-3.23%)

EYPT EyePoint
$13.20 /

-0.44 (-3.23%)

01/27/21 Cantor Fitzgerald
Cantor Fitzgerald starts EyePoint at Overweight with $22 price target
01/27/21 Cantor Fitzgerald
EyePoint initiated with an Overweight at Cantor Fitzgerald
01/12/21 B. Riley
EyePoint price target raised to $8.50 from $5 at B. Riley Securities
01/07/21 Alliance Global Partners
Iluvien deal shows valuation disconnect at Alimera, says Alliance Global Partners
EYPT EyePoint
$13.20 /

-0.44 (-3.23%)

  • 02
    Feb
  • 21
    Feb
Over a quarter ago
Syndicate
EyePoint 9.1M share Spot Secondary priced at $11.00 » 06:07
02/02/21
02/02
06:07
02/02/21
06:07
EYPT

EyePoint

$11.41 /

+0.25 (+2.24%)

The deal priced below the…

The deal priced below the last closing price of $11.48. Cowen and Guggenheim are acting as joint book running managers for the offering.

ShowHide Related Items >><<
EYPT EyePoint
$11.41 /

+0.25 (+2.24%)

EYPT EyePoint
$11.41 /

+0.25 (+2.24%)

01/27/21 Cantor Fitzgerald
Cantor Fitzgerald starts EyePoint at Overweight with $22 price target
01/27/21 Cantor Fitzgerald
EyePoint initiated with an Overweight at Cantor Fitzgerald
01/12/21 B. Riley
EyePoint price target raised to $8.50 from $5 at B. Riley Securities
01/07/21 Alliance Global Partners
Iluvien deal shows valuation disconnect at Alimera, says Alliance Global Partners
EYPT EyePoint
$11.41 /

+0.25 (+2.24%)

  • 02
    Feb
  • 21
    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.